Sitagliptin-induced hemolysis

Ragini Bekur, M. V. Nagaraja, K. N. Shivashankara, Weena Stanley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The advantages are the absence of hypoglycemia when used as monotherapy and they cause less gain weight. We report a case of sitagliptin-induced hemolysis, a rare side effect, not reported in the literature. As sitagliptin is widely used in type 2 diabetes mellitus physicians should be aware of the possibility of this rare but potentially serious adverse drug reaction.

Original languageEnglish
Pages (from-to)320-321
Number of pages2
JournalIndian Journal of Pharmacology
Volume42
Issue number5
DOIs
Publication statusPublished - 01-10-2010

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Sitagliptin-induced hemolysis'. Together they form a unique fingerprint.

  • Cite this

    Bekur, R., Nagaraja, M. V., Shivashankara, K. N., & Stanley, W. (2010). Sitagliptin-induced hemolysis. Indian Journal of Pharmacology, 42(5), 320-321. https://doi.org/10.4103/0253-7613.70405